Oral pill aims to keep deadly blood cancer at bay
NCT ID NCT07458542
Summary
This study is looking at how well an oral medication called ONUREG (azacitidine) works in real-world settings to help keep acute myeloid leukemia (AML) from coming back. It involves 44 adults in Hong Kong who have achieved remission after initial chemotherapy but cannot or choose not to have a stem cell transplant. The main goal is to see how long patients stay cancer-free and to monitor the safety of this maintenance treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Hong Kong
Hong Kong, China
Conditions
Explore the condition pages connected to this study.